The Pathophysiology of Cardiac Hypertrophy and Heart Failure

William E. Stansfield, Mark Ranek, Avani Pendse, Jonathan C. Schisler, Shaobin Wang, Thomas Pulinilkunnil, Monte S. Willis

Research output: Chapter in Book/Report/Conference proceedingChapter


Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

Original languageEnglish (US)
Title of host publicationCellular and Molecular Pathobiology of Cardiovascular Disease
PublisherElsevier Inc.
Number of pages28
ISBN (Print)9780124052062
StatePublished - Jan 2014


  • Calcineurin
  • Congestive heart failure (CHF)
  • FAK
  • GPCR
  • HDAC
  • Hypertrophy
  • Left ventricular hypertrophy (LVH)
  • MAPK
  • MTOR
  • MicroRNA
  • Mitochondria
  • NFAT
  • NO
  • Pathologic hypertrophy
  • Proteasome
  • Reactive oxygen species (ROS)
  • SRF
  • TNF
  • Ubiquitin

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'The Pathophysiology of Cardiac Hypertrophy and Heart Failure'. Together they form a unique fingerprint.

Cite this